Sandoz Inc., a division of Swiss pharmaceutical giant Novartis, and US company Pear Therapeutics announced this week that the the U.S. Food and Drug Administration (FDA) has approved an app that can be prescribed to help treat opium addicts.This content was published on December 16, 2018 - 16:13
For patients 18 years or older who are currently under the supervision of a clinician, reSET-O is indicated as a prescription-only mobile medical application, Novartis noted in a media statement.
As a digital therapist, the app is intended to protect patients from relapses with interactive dialogues. Every day, approximately 115 Americans die after overdosing on opioids.
"Digital technologies and data science have incredible potential to unlock the next chapter of medical innovation and to help individuals finally take control of their own health in a meaningful way," said Sandoz CEO Richard Francis. "New digital therapeutics such as reSET-O also have the potential to fundamentally change how patients interact with their therapies and thus improve patient outcomes. At Sandoz, we are proud to be a joint pioneer in this exciting new field."
The Novartis generics subsidiary Sandoz is responsible for marketing the application prescribed by the physician. In the spring, Sandoz signed a cooperation agreement with Pear Therapeutics. Sandoz says it hopes to be able to charge $15 (CHF15) per month for the app. However, the price is not yet definite, the NZZ am Sonntag reported.
The US regulatory authority has been convinced by its success. Over 12 weeks, 170 patients participated in an opiate withdrawal program. All received a replacement drug. However, 82.4% of those who used the app remained in the program. In the group without a supportive app, only 68.4% managed the full three months, the FDA reported in a press release.
In the United States, 48.5 million people are addicted to drugs. About 18.5% of the adult population consume illegal drugs such as heroin or abuse legal substances such as painkillers. Alcoholics are not included in the figures.
The statistics also reflect the devastating opium dependence of broad sections of the population. The problem is widely blamed on the lax prescription practice of new, supposedly non-addictive painkillers since the 1990s. The “economic burden” of this epidemic amounts to $78.5 billion annually, according to the Centers for Disease Control and Prevention.
This article was automatically imported from our old content management system. If you see any display errors, please let us know: firstname.lastname@example.org